Printer Friendly

HAUSER ANNOUNCES RAPID PROGRESS IN TAXOL PRODUCTION AND NEW TAXANE DEVELOPMENT

 BOULDER, Colo., Jan. 11 /PRNewswire/ -- Hauser Chemical Research Inc. (NASDAQ: HAUS), the only commercial producer of Good Manufacturing Practices (GMP) Taxol, announced today that its production facility is complete and December 1992 production exceeded the design capacity rate of 100 kilograms of Taxol per year. At the request of Bristol-Myers Squibb (Bristol) (NYSE: BMY), expansion of the facility to a capacity of 200 kilograms of Taxol per year by the fall of 1993, is now underway and ahead of schedule.
 According to Dr. Dean P. Stull, Hauser chief executive officer, "It is very exciting that Hauser's efforts over the last five years in the supply of Taxol have contributed to the Food and Drug Administration (FDA) approval of Taxol." Approval was given Dec. 29, 1992, just five months from the filing of the New Drug Application (NDA) by Bristol in July.
 Currently, Hauser is in the second year of a three-year supply agreement with Bristol which contains two, two-year extension options. The contract is valued at over $100,000,000. The contract calls for Hauser to supply Taxol from various raw materials. Although the bark of the Pacific Yew tree is currently the only FDA acceptable raw material, in the future Taxol may be produced from other raw materials and semi-synthesis.
 Over the next eight months, Hauser's original Gunbarrel Taxol facility will be converted to use yew needles, yew clippings and cultivated yew trees for the production of Taxol, 10-deacetylbaccatin III (10-DAB) which is a starting material to make semi-synthetic Taxol, and other taxanes (Taxol-like molecules). The first significant quantities of cultivated yew material is expected to be available this summer.
 Hauser's advanced technology for the production of Taxol has been improved over the past three years and applied to numerous raw materials. Research and process improvements at Hauser are resulting in more efficient processes with higher yields from raw materials. The overall process now takes 10 steps and less than 21 days to complete. Hauser's process yields Taxol and a semi-purified 10-DAB that is finished in 3 steps.
 Hauser has isolated other taxanes from several raw materials. These taxanes are crucial new compounds for the preparation of Taxol derivatives, for which Hauser has patents pending. Several of these patentable derivatives, in laboratory testing, show excellent tubulin binding activity.
 Hauser Chemical Research is a chemical processor, specializing in the extraction and purification of high value natural products using its proprietary technologies. The company provides interdisciplinary laboratory testing services, chemical engineering services and contract research and development through its Hauser Laboratories Division. The company is based in Boulder.
 -0- 1/11/93
 /CONTACT: Dean P. Stull or William E. Paukert, of Hauser Chemical Research, 303-443-4662/
 (HAUS BMY)


CO: Hauser Chemical Research Inc.; Bristol-Myers Squibb ST: Colorado IN: MTC CHM SU:

LA -- DV002 -- 3507 01/11/93 11:43 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 11, 1993
Words:468
Previous Article:FLORA WALKER ELECTED PRESIDENT OF MICHIGAN AFSCME COUNCIL 25
Next Article:HARDEE POWER STATION BEGINS FULL COMMERCIAL OPERATION
Topics:


Related Articles
HAUSER TO DOUBLE TAXOL PRODUCTION CAPACITY AT NEW FACILITY
ESCAGENETICS SIGNS COLLABORATION WITH GENENCOR TO SCALE-UP TAXOL PRODUCTION
HAUSER AFFIRMS PRIVATE LAND HARVEST AND CONTINUED INCREASES IN TAXOL ACTIVITIES
HAUSER NORTHWEST HONORS PRIVATE LANDOWNERS
HAUSER AWARDED NEW PROJECT FROM THE NATIONAL CANCER INSTITUTE FOR A COMPOUND WITH POSSIBLE ANTI-HIV ACTIVITY
HAUSER ANNOUNCES THAT ITS SUPPLY AGREEMENT WITH BRISTOL-MYERS/SQUIBB FOR PACLITAXEL (TAXOL) WILL NOT BE EXTENDED
HAUSER ANNOUNCES PACLITAXEL RESEARCH & COMMERCIALIZATION AGREEMENTS
HAUSER ANNOUNCES AGREEMENT WITH COLGATE ORAL PHARMACEUTICALS TO PRODUCE SANGUINARIA EXTRACT
Bristol-Myers Squibb & Phyton Agree to Commercialize Innovative Technology For Production of TAXOL(R)
Bristol-Myers Squibb & Phyton Agree to Commercialize Innovative Technology for Production of TAXOL(R)

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters